Unknown PHASE4 INTERVENTIONAL 2-arm NCT05364385

Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease (STOPCLD)

Intra-tracheal Instillation of Budesonide Along With Surfactant in Preterm Infants to Prevent Chronic Lung Disease

Sponsor: University of Arizona

Conditions Acute Lung Injury Budesonide Chronic Lung Disease of Prematurity Infant, Extremely Premature

Interventions Infants in the control group (S/P group) receive placebo (Normal saline 1mL) Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)

Updated 5 times since 2022 Last updated: Oct 31, 2022 Started: Dec 2, 2019 Primary completion: Feb 28, 2023 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Acute Lung Injury and Budesonide, this trial is ongoing. The trial is conducted by University of Arizona and has accumulated 5 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Jan 2025 — Present [monthly]

Unknown PHASE4

Status: Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Dec 2022 — Jul 2024 [monthly]

Recruiting PHASE4
Jun 2022 — Dec 2022 [monthly]

Recruiting PHASE4

First recorded

Dec 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Arizona

Data source: University of Arizona

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tucson, United States